TY  - JOUR
AU  - Borrego Izquierdo, Yolanda
AU  - Gomez Fernandez, Encarnacion
AU  - Monje Agudo, Patricia
AU  - Jimenez Galan, Rocio
AU  - Almeida-Gonzalez, Carmen V.
AU  - Ferrit Martin, Monica
AU  - Morillo Verdugo, Ramon
PY  - 2016
DO  - 10.1136/ejhpharm-2015-000822
SN  - 2047-9956
UR  - http://hdl.handle.net/10668/19035
T2  - European journal of hospital pharmacy
AB  - Background There are currently five approved nucleos(t)ide analogues (NUCs) for the management of chronic hepatitis B (CHB): lamivudine, adefovir dipivoxil, telbivudine, entecavir, and tenofovir disoproxil fumarate.Objective To determine the...
LA  - en
PB  - Bmj publishing group
KW  - Hepatitis B
KW  - Persistence
KW  - Treatment
KW  - Nucleoside analogues
KW  - Nucleotide analogues
KW  - Phamaceutical care
KW  - Long-term persistence
KW  - Medication compliance
KW  - Adherence
KW  - Protease
KW  - Outcomes
KW  - Therapy
TI  - Persistence profile to nucleos(t)ide analogue treatment for patients with chronic hepatitis B
TY  - research article
VL  - 23
ER  -